MA53189B2 - Composition pharmaceutique destinée au traitement de l'anémie aplasique - Google Patents
Composition pharmaceutique destinée au traitement de l'anémie aplasiqueInfo
- Publication number
- MA53189B2 MA53189B2 MA53189A MA53189A MA53189B2 MA 53189 B2 MA53189 B2 MA 53189B2 MA 53189 A MA53189 A MA 53189A MA 53189 A MA53189 A MA 53189A MA 53189 B2 MA53189 B2 MA 53189B2
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- week
- treatment
- aplastic anemia
- romiplostim
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition pharmaceutique destinée au traitement de l'anémie aplasique, ladite composition contenant du romiplostim en tant qu'ingrédient actif. Cette composition pharmaceutique est caractérisée en ce qu'elle est administrée par voie sous-cutanée une fois par semaine ; et en ce que pendant les quatre premières semaines suivant le début de l'administration, la quantité administrée de romiplostim est de 10 µg/kg/semaine, puis à partir de la cinquième semaine, la quantité de romiplostim est augmentée au-delà de 10 µg/kg/semaine, jusqu'à 20 µg/kg/semaine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018202097 | 2018-10-26 | ||
| PCT/JP2019/041814 WO2020085467A1 (fr) | 2018-10-26 | 2019-10-25 | Composition pharmaceutique destinée au traitement de l'anémie aplasique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53189A1 MA53189A1 (fr) | 2021-12-31 |
| MA53189B2 true MA53189B2 (fr) | 2023-09-27 |
Family
ID=70332110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53189A MA53189B2 (fr) | 2018-10-26 | 2019-10-25 | Composition pharmaceutique destinée au traitement de l'anémie aplasique |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210379154A1 (fr) |
| EP (1) | EP3881856B1 (fr) |
| JP (2) | JPWO2020085467A1 (fr) |
| KR (1) | KR20210087045A (fr) |
| CN (1) | CN112888453A (fr) |
| AU (1) | AU2019364063A1 (fr) |
| BR (1) | BR112021007710A2 (fr) |
| CA (1) | CA3117477A1 (fr) |
| EA (1) | EA202191130A1 (fr) |
| IL (1) | IL282470A (fr) |
| MA (1) | MA53189B2 (fr) |
| MX (1) | MX2021004551A (fr) |
| SG (1) | SG11202104199WA (fr) |
| TW (1) | TW202021611A (fr) |
| WO (1) | WO2020085467A1 (fr) |
| ZA (1) | ZA202102940B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114027263A (zh) * | 2021-12-01 | 2022-02-11 | 上海中医药大学 | 一种获得性再生障碍性贫血模型小鼠的生产方法 |
| WO2023149443A1 (fr) * | 2022-02-02 | 2023-08-10 | 国立大学法人 筑波大学 | Composition pharmaceutique pour la récupération des cellules sanguines après une greffe de sang de cordon |
| WO2024028744A1 (fr) * | 2022-08-01 | 2024-02-08 | Zydus Lifesciences Limited | Traitement de l'anémie aplasique (aa) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3820105B2 (ja) * | 1998-10-23 | 2006-09-13 | キリン−アムジエン・インコーポレーテツド | Ｍｐ１受容体に結合し血小板生成活性を有する二量体トロンボポエチンペプチド模倣体 |
| WO2002015926A1 (fr) * | 2000-08-24 | 2002-02-28 | Kirin Beer Kabushiki Kaisha | Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes |
| JP6559185B2 (ja) | 2017-06-09 | 2019-08-14 | 株式会社カプコン | ゲームプログラムおよびゲーム装置 |
-
2019
- 2019-10-25 US US17/288,057 patent/US20210379154A1/en active Pending
- 2019-10-25 EP EP19875343.6A patent/EP3881856B1/fr active Active
- 2019-10-25 MA MA53189A patent/MA53189B2/fr unknown
- 2019-10-25 WO PCT/JP2019/041814 patent/WO2020085467A1/fr unknown
- 2019-10-25 KR KR1020217015296A patent/KR20210087045A/ko active Search and Examination
- 2019-10-25 CA CA3117477A patent/CA3117477A1/fr active Pending
- 2019-10-25 CN CN201980069759.6A patent/CN112888453A/zh active Pending
- 2019-10-25 MX MX2021004551A patent/MX2021004551A/es unknown
- 2019-10-25 EA EA202191130A patent/EA202191130A1/ru unknown
- 2019-10-25 JP JP2020552613A patent/JPWO2020085467A1/ja active Pending
- 2019-10-25 TW TW108138718A patent/TW202021611A/zh unknown
- 2019-10-25 SG SG11202104199WA patent/SG11202104199WA/en unknown
- 2019-10-25 AU AU2019364063A patent/AU2019364063A1/en active Pending
- 2019-10-25 BR BR112021007710-3A patent/BR112021007710A2/pt unknown
-
2021
- 2021-04-20 IL IL282470A patent/IL282470A/en unknown
- 2021-04-30 ZA ZA2021/02940A patent/ZA202102940B/en unknown
-
2024
- 2024-06-19 JP JP2024098449A patent/JP2024123116A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA53189A1 (fr) | 2021-12-31 |
| ZA202102940B (en) | 2022-10-26 |
| AU2019364063A1 (en) | 2021-06-10 |
| KR20210087045A (ko) | 2021-07-09 |
| EP3881856B1 (fr) | 2024-08-07 |
| EA202191130A1 (ru) | 2021-07-22 |
| SG11202104199WA (en) | 2021-05-28 |
| TW202021611A (zh) | 2020-06-16 |
| MX2021004551A (es) | 2021-07-16 |
| CN112888453A (zh) | 2021-06-01 |
| EP3881856A1 (fr) | 2021-09-22 |
| JPWO2020085467A1 (ja) | 2021-09-16 |
| WO2020085467A1 (fr) | 2020-04-30 |
| JP2024123116A (ja) | 2024-09-10 |
| EP3881856A4 (fr) | 2022-06-29 |
| US20210379154A1 (en) | 2021-12-09 |
| CA3117477A1 (fr) | 2020-04-30 |
| BR112021007710A2 (pt) | 2021-08-10 |
| IL282470A (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53189A1 (fr) | Composition pharmaceutique destinée au traitement de l'anémie aplasique | |
| MA44206A (fr) | Comprimé orodispersible comprenant estetrol | |
| US20160136231A1 (en) | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions | |
| EA201991299A1 (ru) | Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MA45972B1 (fr) | Unité posologique orodispersible contenant un composant d'estétrol | |
| MA44205B1 (fr) | Comprimé orodispersible comprenant estetrol | |
| MA33057B1 (fr) | Composition pharmaceutique solide comprenant de l'amlodipine et du losartan | |
| EA202090573A1 (ru) | Составы нирапариба | |
| MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| EA202190115A1 (ru) | Пленочные составы, содержащие дексмедетомидин, и способы их получения | |
| MA38688A1 (fr) | Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d | |
| MA54663A1 (fr) | Composition pharmaceutique aqueuse d'un anticorps anti-il17a et son utilisation | |
| JP2019507786A5 (fr) | ||
| EP4233850A3 (fr) | Formulations de capsules | |
| TWI250023B (en) | Pharmaceutical composition for itch treating agent | |
| ECSP066476A (es) | Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| JP6509244B2 (ja) | 水晶体硬化抑制剤 | |
| MA58507A1 (fr) | Composition pharmaceutique aqueuse de levilimab | |
| Khardori et al. | Infection, immunity, and hormones/endocrine interactions | |
| MA53521B1 (fr) | Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications | |
| MA61742A1 (fr) | Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation | |
| Gonçalves et al. | Immunosuppressant therapy and bone loss in ligature-induced periodontitis: a study in rats |